INO, MRNA, NVAX, EBS Surge Overnight: Trump Promises Full Hantavirus Report as Outbreak Sparks Vaccine Rally

• Trump stated that the administration will publish a comprehensive report regarding the Hantavirus on Friday.

・Three fatalities, six confirmed cases, and more suspected infections have been reported following an outbreak on the Dutch-registered cruise ship Hondius.

・Moderna gained recognition because of its hantavirus vaccine collaboration with Korea University.

Stocks of vaccine manufacturers and biodefense firms rose overnight on Friday following U.S. President Donald Trump's comments about a deadly hantavirus outbreak on a cruise ship and his promise to provide a complete update on the matter.

Overnight, Emergent BioSolutions (EBS) climbed 3%, while Inovio Pharmaceuticals (INO) and Novavax (NVAX) each gained 2% and Moderna (MRNA) rose 1%.

Trump Vows to Release Complete Hantavirus Report

Trump stated late Thursday that the administration is closely examining the outbreak on the Dutch-flagged cruise ship Hondius, where three passengers have passed away and several others have been infected. "It's very much, we hope, under control," Trump said, noting that a complete report will be issued on Friday.

The outbreak has resulted in six confirmed infections and more suspected cases on the ship, which carried 150 passengers during a transatlantic journey from Argentina to Europe. Officials are still looking into how the virus was transmitted aboard.

Singapore has already placed two passengers from the ship in isolation due to worries about potential exposure during their journey. The World Health Organization (WHO) has also issued a warning regarding the outbreak, but officials stated that the global risk is still low and that hantavirus spreads less easily than COVID-19 or the flu. The virus in question is believed to be the Andes strain, one of the few hantavirus types that can spread between people to a limited extent.

Moderna's Hantavirus Initiative Reemerges as Priority

Moderna is considered one of the U.S. government's primary vaccine systems for managing outbreaks. Since 2023, the company has collaborated with the Vaccine Innovation Center at Korea University to develop an mRNA-based hantavirus vaccine, with early preclinical research this year demonstrating protection against hantavirus infection in mice.

In 2024, Moderna was granted a $176 million funding from the Biomedical Advanced Research and Development Authority (BARDA) for the creation of mRNA-based vaccines against pandemic influenza and for outbreak readiness initiatives. The company's collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) is also being highlighted, as CEPI had previously stated that mRNA technology could reduce vaccine development periods to as few as 100 days during outbreaks.

Inovio: Direct Hantavirus Play

Inovio, on the other hand, has the strongest connection to hantavirus among the stocks that rose overnight. The company has been involved in multiple hantavirus DNA vaccine studies targeting Hantaan, Puumala, and Andes hantavirus strains. One study funded by the National Institute of Allergy and Infectious Diseases tested an Andes virus DNA vaccine to prevent hantavirus pulmonary syndrome, while another study supported by the U.S. Army looked into combined hantavirus DNA vaccines.

Although none of Inovio's hantavirus vaccine initiatives led to a marketable product, the outbreak reignited investor curiosity about firms that had previously conducted hantavirus research.

NVAX, EBS Highlighted in Outbreak Focus

Investors often shift their focus to Novavax when there are news updates about viruses, thanks to the company's vaccine development system and past success in quickly creating candidates for diseases like Ebola, MERS, and Zika. The company's protein-based nanoparticle technology along with its Matrix-M adjuvant can produce vaccine options for new infectious diseases, having already been applied in approved COVID-19 and malaria vaccines.

On the other hand, Emergent BioSolutions is frequently considered one of the key biodefense and medical-countermeasure providers for the U.S. government during public health crises. The company has established partnerships with BARDA and develops products related to Anthrax, Ebola, smallpox, mpox, and viral hemorrhagic fevers. Emergent has previously been awarded BARDA task orders for treatments targeting viral hemorrhagic fevers and has also been involved in production efforts during outbreaks such as Ebola and Zika.

How Do Individual Investors Feel About INO, MRNA, NVAX, EBS?

On [date], retail sentiment for INO and NVAX was 'extremely bullish' despite 'extremely high' message volume, while MRNA showed 'bullish' sentiment with 'high' message volume. EBS also experienced 'extremely bullish' sentiment, although message volume stayed 'normal.'

In the last year, MRNA has increased by 102%, EBS has risen 93%, and NVAX has gone up 55%, whereas INO has dropped 22%.

For information and revisions, send an email to newsroom[at][dot]com.

INSPIRATIONS DIGITAL